Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Erratum. Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785-1787.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2018 Apr;41(4):913. doi: 10.2337/dc18-er04a. Epub 2018 Feb 23. No abstract available.

2.

The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1.

Sosenko JM, Geyer S, Skyler JS, Rafkin LE, Ismail HM, Libman IM, Liu YF, DiMeglio LA, Evans-Molina C, Palmer JP.

Pediatr Diabetes. 2018 May;19(3):403-409. doi: 10.1111/pedi.12609. Epub 2017 Nov 24.

PMID:
29171129
3.

The shape of the glucose concentration curve during an oral glucose tolerance test predicts risk for type 1 diabetes.

Ismail HM, Xu P, Libman IM, Becker DJ, Marks JB, Skyler JS, Palmer JP, Sosenko JM; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2018 Jan;61(1):84-92. doi: 10.1007/s00125-017-4453-6. Epub 2017 Sep 27.

PMID:
28956083
4.

Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.

Nathan BM, Boulware D, Geyer S, Atkinson MA, Colman P, Goland R, Russell W, Wentworth JM, Wilson DM, Evans-Molina C, Wherrett D, Skyler JS, Moran A, Sosenko JM; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.

PMID:
28860125
5.

Impact of Age and Antibody Type on Progression From Single to Multiple Autoantibodies in Type 1 Diabetes Relatives.

Bosi E, Boulware DC, Becker DJ, Buckner JH, Geyer S, Gottlieb PA, Henderson C, Kinderman A, Sosenko JM, Steck AK, Bingley PJ; Type 1 Diabetes TrialNet Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2881-2886. doi: 10.1210/jc.2017-00569.

PMID:
28531305
6.

The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.

Sosenko JM, Yu L, Skyler JS, Krischer JP, Gottlieb PA, Boulware D, Miao D, Palmer JP, Steck AK.

Diabetes Technol Ther. 2017 Mar;19(3):183-187. doi: 10.1089/dia.2016.0243. Epub 2017 Feb 8.

7.

Diabetic Neuropathy: A Position Statement by the American Diabetes Association.

Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, Sosenko JM, Ziegler D.

Diabetes Care. 2017 Jan;40(1):136-154. doi: 10.2337/dc16-2042. Review. No abstract available.

PMID:
27999003
8.

Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis.

Skyler JS, Bakris GL, Bonifacio E, Darsow T, Eckel RH, Groop L, Groop PH, Handelsman Y, Insel RA, Mathieu C, McElvaine AT, Palmer JP, Pugliese A, Schatz DA, Sosenko JM, Wilding JP, Ratner RE.

Diabetes. 2017 Feb;66(2):241-255. doi: 10.2337/db16-0806. Epub 2016 Dec 15. Review.

9.

Staging the progression to type 1 diabetes with prediagnostic markers.

Sosenko JM.

Curr Opin Endocrinol Diabetes Obes. 2016 Aug;23(4):297-305. doi: 10.1097/MED.0000000000000267. Review.

10.

The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants.

Meah FA, DiMeglio LA, Greenbaum CJ, Blum JS, Sosenko JM, Pugliese A, Geyer S, Xu P, Evans-Molina C; Type 1 Diabetes TrialNet Study Group.

Diabetologia. 2016 Jun;59(6):1186-95. doi: 10.1007/s00125-016-3924-5. Epub 2016 Mar 19.

11.

HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression.

Pugliese A, Boulware D, Yu L, Babu S, Steck AK, Becker D, Rodriguez H, DiMeglio L, Evans-Molina C, Harrison LC, Schatz D, Palmer JP, Greenbaum C, Eisenbarth GS, Sosenko JM; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2016 Apr;65(4):1109-19. doi: 10.2337/db15-1105. Epub 2016 Jan 28.

12.

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.

Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG.

Diabetes Care. 2015 Oct;38(10):1964-74. doi: 10.2337/dc15-1419. Review.

13.

The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).

Sosenko JM, Skyler JS, Palmer JP; Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Curr Diab Rep. 2015 Aug;15(8):49. doi: 10.1007/s11892-015-0626-1. Review.

14.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

15.

β cell death and dysfunction during type 1 diabetes development in at-risk individuals.

Herold KC, Usmani-Brown S, Ghazi T, Lebastchi J, Beam CA, Bellin MD, Ledizet M, Sosenko JM, Krischer JP, Palmer JP; Type 1 Diabetes TrialNet Study Group.

J Clin Invest. 2015 Mar 2;125(3):1163-73. doi: 10.1172/JCI78142. Epub 2015 Feb 2.

16.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

17.

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.

18.

Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Skyler JS, Beam CA, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2013 Dec;62(12):4179-83. doi: 10.2337/db13-0656. Epub 2013 Jul 17.

19.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

20.

The evolution of type 1 diabetes.

Skyler JS, Sosenko JM.

JAMA. 2013 Jun 19;309(23):2491-2. doi: 10.1001/jama.2013.6286. No abstract available.

PMID:
23780463
21.

Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis.

Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2012 Oct;35(10):1975-80. Epub 2012 Jul 11.

22.

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, Skyler JS, Sosenko JM; Type 1 Diabetes TrialNet Study Group.

Diabetes. 2012 Aug;61(8):2066-73. Epub 2012 Jun 11.

23.

The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1.

Sosenko JM, Skyler JS, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes. 2012 Jun;61(6):1331-7. doi: 10.2337/db11-1660. Review. No abstract available.

24.

The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2012 Jul;35(7):1552-5. doi: 10.2337/dc12-0011. Epub 2012 Apr 30.

25.

Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies.

Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL; Type 1 Diabetes TrialNet Study Group.

Diabetes Care. 2012 Jun;35(6):1213-8. doi: 10.2337/dc11-2081. Epub 2012 Mar 23.

26.

A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Cuthbertson D, Yu L, Schatz DA, Orban T, Eisenbarth G; Diabetes Prevention Trial–Type 1 and Type 1 Diabetes TrialNet Study Groups.

Diabetes Care. 2011 Nov;34(11):2435-7. doi: 10.2337/dc11-0981. Epub 2011 Sep 12.

27.

Development of autoantibodies in the TrialNet Natural History Study.

Vehik K, Beam CA, Mahon JL, Schatz DA, Haller MJ, Sosenko JM, Skyler JS, Krischer JP; TrialNet Natural History Study Group.

Diabetes Care. 2011 Sep;34(9):1897-901. doi: 10.2337/dc11-0560. Epub 2011 Jul 12.

28.

Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2011 Aug;34(8):1785-7. doi: 10.2337/dc11-0641. Epub 2011 Jun 16. Erratum in: Diabetes Care. 2018 Feb 23;:.

29.

Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood.

Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2011 Feb;34(2):358-62. doi: 10.2337/dc10-1494.

30.

Prognostic performance of metabolic indexes in predicting onset of type 1 diabetes.

Xu P, Wu Y, Zhu Y, Dagne G, Johnson G, Cuthbertson D, Krischer JP, Sosenko JM, Skyler JS; Diabetes Prevention Trial-Type 1 (DPT-1) Study Group.

Diabetes Care. 2010 Dec;33(12):2508-13. doi: 10.2337/dc10-0802. Epub 2010 Aug 31.

31.

Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1).

Sosenko JM, Skyler JS, Krischer JP, Greenbaum CJ, Mahon J, Rafkin LE, Cuthbertson D, Cowie C, Herold K, Eisenbarth G, Palmer JP; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes. 2010 Oct;59(10):2386-9. doi: 10.2337/db10-0534. Epub 2010 Aug 3.

32.

A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.

Sosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS; Diabetes Prevention Trial-Type 1 and TrialNet Study Groups.

Pediatr Diabetes. 2011 Mar;12(2):85-90. doi: 10.1111/j.1399-5448.2010.00662.x.

33.

Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants.

Sosenko JM, Palmer JP, Rafkin LE, Krischer JP, Cuthbertson D, Greenbaum CJ, Eisenbarth G, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2010 Mar;33(3):620-5. doi: 10.2337/dc09-1770. Epub 2009 Dec 23.

34.

Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset.

Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS; DPT-1 Study Group.

Diabetes. 2010 Mar;59(3):679-85. doi: 10.2337/db09-1378. Epub 2009 Dec 22.

35.

The prevalence of diabetic neuropathy according to ethnicity.

Sosenko JM.

Curr Diab Rep. 2009 Dec;9(6):435-9. Review.

PMID:
19954688
36.

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2009 Dec;32(12):2269-74. doi: 10.2337/dc09-0934. Epub 2009 Sep 9.

37.

Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2009 Sep;32(9):1603-7. doi: 10.2337/dc08-2140. Epub 2009 Jun 1.

38.

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group.

Pediatr Diabetes. 2009 Apr;10(2):97-104. doi: 10.1111/j.1399-5448.2008.00464.x. Epub 2008 Sep 24.

PMID:
18823409
39.

Glucose and C-peptide changes in the perionset period of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Matheson D, Skyler JS.

Diabetes Care. 2008 Nov;31(11):2188-92. doi: 10.2337/dc08-0935. Epub 2008 Jul 23.

40.

A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2008 Mar;31(3):528-33. Epub 2007 Nov 13.

PMID:
18000175
41.

Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2007 Jan;30(1):38-42.

PMID:
17192330
42.

Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS.

Diabetes Care. 2006 Mar;29(3):643-9.

PMID:
16505520
43.

A comparison of the monofilament with other testing modalities for foot ulcer susceptibility.

Miranda-Palma B, Sosenko JM, Bowker JH, Mizel MS, Boulton AJ.

Diabetes Res Clin Pract. 2005 Oct;70(1):8-12. Epub 2005 Mar 28.

PMID:
16126117
44.

Diabetic neuropathies: a statement by the American Diabetes Association.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; American Diabetes Association.

Diabetes Care. 2005 Apr;28(4):956-62. Review. No abstract available.

PMID:
15793206
45.

Incidence of lower-extremity amputation in American Indians: the Strong Heart Study.

Resnick HE, Carter EA, Sosenko JM, Henly SJ, Fabsitz RR, Ness FK, Welty TK, Lee ET, Howard BV; Strong Heart Study.

Diabetes Care. 2004 Aug;27(8):1885-91.

PMID:
15277412
46.

Sensory function and albumin excretion according to diagnostic criteria for diabetes.

Sosenko JM, Kato M, Goldberg RB.

Diabetes Care. 2004 Jul;27(7):1716-20.

PMID:
15220252
47.

Diabetic somatic neuropathies.

Boulton AJ, Malik RA, Arezzo JC, Sosenko JM.

Diabetes Care. 2004 Jun;27(6):1458-86. Review. No abstract available.

PMID:
15161806
48.

Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study.

Sosenko JM, Hu D, Welty T, Howard BV, Lee E, Robbins DC; Strong Heart Study.

Diabetes Care. 2002 Jun;25(6):1078-84.

PMID:
12032118
49.

Use of the Semmes-Weinstein monofilament in the strong heart study. Risk factors for clinical neuropathy.

Sosenko JM, Sparling YH, Hu D, Welty T, Howard BV, Lee E, Robbins DC.

Diabetes Care. 1999 Oct;22(10):1715-21.

50.

The degree of blood pressure evaluation and end organ damage with severe hypertension: a case-control study.

Fournier AM, Hoenig LJ, Sosenko JM.

Am J Med Sci. 1993 Dec;306(6):367-70.

PMID:
8266976

Supplemental Content

Loading ...
Support Center